Antitrust

CCI approves proposed transaction involving the sale of the global biosimilars portfolio of Viatris Inc. to Biocon Biologics Limited (Biocon Biologics) and an equity infusion in Biocon Biologics by Biocon and Serum (Proposed Transaction).

CCI approves proposed transaction involving the sale of the global biosimilars
portfolio of Viatris Inc. to Biocon Biologics Limited (Biocon Biologics) and an equity
infusion in Biocon Biologics by Biocon and Serum (Proposed Transaction).

Date 14/06/2022
 
Press Release (259.85 KB)